EYLEA Recent News
The Prospects For CHS-3351, Coherus' Most Underappreciated Asset
Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored
Do Analysts See A Path Forward For Ophthotech's Fovista?
Stay Of Court Injunction A Mild Positive For Regeneron
Regeneron Eyes A Comeback In 2017
One Way To Look At The Ophthotech-Regeneron Pair Trade
Imprimis Pharmaceutical After Its Phenomenal Quarter: 'Shocking' Statistics, Simplification And A Trifecta For Success
Regeneron Is 'One Of The Stronger Growers In Biotech'
Regeneron Gains 4% Following Q1 Earnings Release
Regeneron Pharmaceuticals Loses 7% Following Q4 Miss
Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns
Why Avalanche Biotechnologies Is Coming Off A Big Day
Regeneron Earnings: Small Growth Expected, Driven By Eylea
UPDATE: Barclays Initiates Coverage On Regeneron
Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments
Top Trending Tickers On StockTwits For February 11